# TG Therapeutics, Inc. clinical trials: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with TG Therapeutics, Inc. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by TG Therapeutics, Inc.: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 2, 2026 | NCT07680946 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia | TG Therapeutics, Inc. | Phase 2 | Recruiting | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680946) |
| June 29, 2026 | NCT07673744 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Myasthenia Gravis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673744) |
| May 11, 2026 | NCT07577583 | Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel | TG Therapeutics, Inc. | Observational | Recruiting | B-cell Mediated Autoimmune Disorders | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577583) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |
| October 23, 2025 | NCT07220252 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | TG Therapeutics, Inc. | Phase 2/3 | Recruiting | Relapsing Multiple Sclerosis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220252) |
| October 8, 2025 | NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in... | TG Therapeutics, Inc. | Phase 3 | Active not recruiting | Relapsing Multiple Sclerosis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211633) |
| November 8, 2024 | NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | TG Therapeutics, Inc. | Phase 1 | Recruiting | B-cell Mediated Autoimmune Disorders | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680037) |
| May 30, 2024 | NCT06433765 | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) | TG Therapeutics, Inc. | Observational | Recruiting | Multiple Sclerosis | 728 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433765) |
| May 30, 2024 | NCT06433752 | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | TG Therapeutics, Inc. | Observational | Recruiting | Relapsing Multiple Sclerosis, Multiple Sclerosis | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433752) |
| November 22, 2023 | NCT06143514 | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | TG Therapeutics, Inc. | Observational | Active not recruiting | Relapsing Multiple Sclerosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06143514) |
| May 26, 2023 | NCT05877963 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | TG Therapeutics, Inc. | Phase 3 | Recruiting | Relapsing Multiple Sclerosis | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05877963) |
| March 19, 2021 | NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | TG Therapeutics, Inc. | Phase 1 | Terminated | CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04806035) |
| October 18, 2019 | NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | TG Therapeutics, Inc. | Phase 3 | Active not recruiting | Relapsing Multiple Sclerosis (RMS) | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04130997) |
| July 11, 2019 | NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently... | TG Therapeutics, Inc. | Phase 2 | Terminated | Chronic Lymphocytic Leukemia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04016805) |
| February 4, 2019 | NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | TG Therapeutics, Inc. | Phase 2 | Terminated | Follicular Lymphoma, Small Lymphocytic Lymphoma | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03828448) |
| January 15, 2019 | NCT03804996 | Study of TG-1801 in Subjects With B-Cell Lymphoma | TG Therapeutics, Inc. | Phase 1 | Completed | B-Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03804996) |
| January 11, 2019 | NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination... | TG Therapeutics, Inc. | Phase 2/3 | Terminated | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03801525) |
| December 19, 2018 | NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | TG Therapeutics, Inc. | Phase 1 | Terminated | B-cell Non Hodgkin Lymphoma, Richter's Transformation | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03778073) |
| September 14, 2018 | NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | TG Therapeutics, Inc. | Phase 1 | Terminated | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03671590) |
| December 21, 2017 | NCT03381170 | An Extension of the TG1101-RMS201 Trial | TG Therapeutics, Inc. | Phase 2 | Completed | Relapsing Remitting Multiple Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03381170) |
| December 20, 2017 | NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory... | TG Therapeutics, Inc. | Phase 1/2 | Terminated | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03379051) |
| December 6, 2017 | NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | TG Therapeutics, Inc. | Phase 2 | Completed | Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03364231) |
| September 11, 2017 | NCT03277261 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | TG Therapeutics, Inc. | Phase 3 | Completed | Relapsing Multiple Sclerosis (RMS) | 549 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03277261) |
| September 11, 2017 | NCT03277248 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | TG Therapeutics, Inc. | Phase 3 | Completed | Relapsing Multiple Sclerosis (RMS) | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03277248) |
| July 2, 2017 | NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab... | TG Therapeutics, Inc. | Phase 2 | Terminated | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03207256) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 3 |
| Phase 2 | 11 |
| Phase 2/3 | 3 |
| Phase 3 | 7 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 13 |
| Recruiting | 9 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Lymphocytic, Chronic, B-Cell | 18 |
| Lymphoma, Non-Hodgkin | 8 |
| Multiple Sclerosis | 6 |
| Lymphoma, B-Cell, Marginal Zone | 5 |
| Lymphoma, B-Cell | 4 |
| Lymphoma, Mantle-Cell | 3 |
| Lymphoma, Follicular | 3 |
| Waldenstrom Macroglobulinemia | 3 |
| Recurrence | 3 |
| Myasthenia Gravis | 2 |
| Hodgkin Disease | 2 |
| Lymphoma | 2 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Pancreatic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Rectal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Schizophrenia | 1 |
| Neuromyelitis Optica | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Farming services in the United States](https://specstream.ai/data/businesses/farming-services/united-states)
